Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002;2001(1):CD000369.
doi: 10.1002/14651858.CD000369.

Interferon for acute hepatitis C

T Poynard  1 , C Regimbeau, R P Myers, T Thevenot, V Leroy, P Mathurin, P Opolon, J P Zarski
Affiliations
Review

Interferon for acute hepatitis C

T Poynard et al. Cochrane Database Syst Rev. 2002.

Abstract

Background: Acute hepatitis C virus (HCV) infection progresses to chronicity in the majority of patients. In order to prevent the progression to chronic disease, several studies have assessed interferon in patients with acute hepatitis C.

Objectives: The aim of this review was to assess the efficacy of interferon in acute HCV infection.

Search strategy: We searched MEDLINE, the Cochrane Controlled Trials Register, and the abstracts of the American Association for the Study of Liver Diseases (June 2001). We also contacted pharmaceutical companies to obtain unpublished trials.

Selection criteria: Randomised clinical trials comparing interferon with placebo or no treatment, and published as an article, abstract, or letter were selected. No language limitations were used.

Data collection and analysis: Two reviewers independently assessed trial quality and extracted data. The following endpoints were analysed: normalization of alanine aminotransferase (ALT) activity at the end of treatment (biochemical ETR); sustained ALT normalization at the end follow-up (biochemical SR); disappearance of serum HCV RNA by polymerase chain reaction assay at the end of treatment (virologic ETR) and at the end of follow-up (virologic SR). Histologic data and adverse events were also recorded. Assessment of drug efficacy used the methods of Peto and Der Simonian and Laird.

Main results: Six randomised trials involving 206 patients with acute hepatitis C met the inclusion criteria. Four trials assessing interferon alfa-2b in 141 patients, all with transfusion-acquired acute hepatitis C, were included. They demonstrated no significant heterogeneity in the outcomes assessed. When compared with no treatment, interferon alfa-2b was associated with an increase in the rates of virologic ETR and SR by 45% (95% CI 31-59%, P < 0.00001) and 29% (95% CI 14-44%, P = 0.0002), respectively. The virologic ETR was 42% (95% CI: 30-56%) in the interferon alfa-2b group versus 4% (95% CI 0-13%, P < 0.00001) in the control group. At the end of follow-up, a virologic SR was seen in 32% (95% CI 21-46%) of interferon-treated patients versus only 4% (95% CI 0-13%, P = 0.00007) of controls. The tolerability of therapy, or the impact of interferon alfa-2b on hepatic histology, was not reported. Two trials assessed interferon beta in a total 65 patients. The efficacy of interferon beta could not be assessed, however, due to heterogeneity of these trials.

Reviewer's conclusions: Interferon alfa is effective in improving biochemical outcomes and achieving sustained virologic clearance in patients with transfusion-acquired acute hepatitis C. The effect on long-term clinical outcomes could not be assessed due to limitations in the current data.

PubMed Disclaimer

Conflict of interest statement

The authors have no permanent financial contracts with companies producing interferon. T. Poynard, P. Opolon, and J.P. Zarski have been involved in prospective studies sponsored by Schering Plough, Roche, Glaxo Welcome, and AMGEN.

Figures

1.1
1.1. Analysis
Comparison 1 Interferon alfa‐2b versus control, Outcome 1 Biochemical ETR.
1.2
1.2. Analysis
Comparison 1 Interferon alfa‐2b versus control, Outcome 2 Biochemical SR.
1.3
1.3. Analysis
Comparison 1 Interferon alfa‐2b versus control, Outcome 3 Virologic ETR.
1.4
1.4. Analysis
Comparison 1 Interferon alfa‐2b versus control, Outcome 4 Virologic SR.
1.5
1.5. Analysis
Comparison 1 Interferon alfa‐2b versus control, Outcome 5 Adverse events.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Calleri 1998 {published data only}
    1. Calleri G, Colombatto P, Gozzelino M, Chieppa F, Romano P, Delmastro B, et al. Natural beta interferon in acute type‐C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol 1998;30(2):181‐4. [MEDLINE: ] - PubMed
Hwang 1994 {published data only}
    1. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha‐2b in the treatment of Chinese patients with acute post‐transfusion hepatitis C. J Hepatol 1994;21(5):831‐6. [MEDLINE: ] - PubMed
Lampertico 1994 {published data only}
    1. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, et al. A multicenter randomized controlled trial of recombinant interferon‐alpha 2b in patients with acute transfusion‐associated hepatitis C. Hepatology 1994;19(1):19‐22. [MEDLINE: ] - PubMed
Li 1993 {published data only}
    1. Li XW, Zhu ZY, Dao WP, Liu FH, Die GS. A report on therapy of interferon alfa 2b in patients with acute hepatitis C. Chung Hua Nei Ko Tsa Chih 1993;32(6):409‐11. [MEDLINE: ] - PubMed
Omata 1991 {published data only}
    1. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338(8772):914‐5. [MEDLINE: ] - PubMed
Viladomiu 1992 {published data only}
    1. Viladomiu L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez‐Talavera JC, et al. Interferon‐alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 1992;15(5):767‐9. [MEDLINE: ] - PubMed

References to studies excluded from this review

Alberti 1994 {published data only}
    1. Alberti A, Chemello L, Belussi F, Pontisso P, Tisminetzky S, Gerotto M, et al. Outcome of acute hepatitis C and role of alpha interferon therapy. In: Nishioka KSH, Oda T editor(s). Viral Hepatitis and Liver Disease. Tokyo, Japan: Springer‐Verlag, 1994:604‐6.
Colombo 1993 {published data only}
    1. Colombo M, Lampertico P, Rumi M. Multicentre randomised controlled trial of recombinant interferon alfa‐2b in patients with acute non‐A, non‐B/type C hepatitis after transfusion. Gut 1993;34(2 Suppl):S141. [MEDLINE: ] - PMC - PubMed
Fukui 1994 {published data only}
    1. Fukui S, Tohyama H, Iwabuchi S. Interferon therapy for acute hepatitis C; changes in serum markers associated with HCV and clinical effects. Nippon Rinsho 1994;52(7):1847‐51. [MEDLINE: ] - PubMed
Genesca 1992 {published data only}
    1. Genesca J. Interferon alfa in acute posttransfusion hepatitis C: a randomized, controlled trial. Gastroenterology 1992;103(5):1702‐3. [MEDLINE: ] - PubMed
Lee 1996 {published data only}
    1. Lee WM, Shiffman ML, Gnann Jr. JW, Samanta A, Alam J. A trial of interferon therapy beta 1a for 4 weeks for therapy of acute hepatitis C (Abstract). Hepatology 1996;24(4 Pt. 2):275A.
Ohnishi 1989 {published data only}
    1. Ohnishi K, Nomura F, Iida S. Treatment of posttransfusion non‐A, non‐B acute and chronic hepatitis with human fibroblast beta‐interferon: a preliminary report. Am J Gastroenterol 1989;84(6):596‐600. [MEDLINE: ] - PubMed
Ohnishi 1991 {published data only}
    1. Ohnishi K, Nomura F, Nakano M. Interferon therapy for acute posttransfusion non‐A, non‐B hepatitis: response with respect to anti‐hepatitis C virus antibody status. Am J Gastroenterol 1991;86(8):1041‐9. [MEDLINE: ] - PubMed
Omata 1994 {published data only}
    1. Omata M, Takano S. A randomized, controlled trial of interferon‐beta treatment for acute hepatitis C. Viral Hepatitis and Liver Disease 1994:601‐3.
Palmovic 1994 {published data only}
    1. Palmovic D, Kurelac I, Crnjakovic‐Palmovic J. The treatment of acute post‐transfusion hepatitis C with recombinant interferon‐alpha. Infection 1994;22(3):222‐3. [MEDLINE: ] - PubMed
Takano 1994 {published data only}
    1. Takano S, Satomura Y, Omata M. Effects of interferon beta on non‐A, non‐B acute hepatitis: a prospective, randomized, controlled‐dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994;107(3):805‐11. [MEDLINE: ] - PubMed
Tassopoulos 1993 {published data only}
    1. Tassopoulos NC, Koutelou MG, Papatheodoridis G, Polychronaki H, Delladetsima I, Giannikakis T, et al. Recombinant human interferon alfa‐2b treatment for acute non‐A, non‐B hepatitis. Gut 1993;34(2):S130‐2. [MEDLINE: ] - PMC - PubMed
Vogel 1996 {published data only}
    1. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, Grunewald K, Patsch J. High dose interferon alpha 2b treatment prevents chronicity in acute hepatitis C. A pilot study. Dig Dis Sci 1996;41(12 Suppl):81S‐85S. [MEDLINE: ] - PubMed

Additional references

Alter 1992
    1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community‐acquired hepatitis C in the United States. The Sentinel Counties Chronic non‐A, non‐B Hepatitis Study Team. N Engl J Med 1992;327(27):1899‐1905. [MEDLINE: ] - PubMed
Armstrong 2000
    1. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31(3):777‐82. [MEDLINE: ] - PubMed
Camma 1996
    1. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta‐analysis. Dig Dis Sci 1996;41(6):1248‐55. [MEDLINE: ] - PubMed
Camma 1997
    1. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta‐analysis. J Hepatol 1997;26(6):1187‐99. [MEDLINE: ] - PubMed
Davis 1989
    1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321(22):1501‐6. [MEDLINE: ] - PubMed
DeMets 1987
    1. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Stat Med 1987;6(3):341‐8. [MEDLINE: ] - PubMed
Der Simonian 1986
    1. Simonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clin Trials 1986;7:177‐88. [MEDLINE: ] - PubMed
Donahue 1992
    1. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of post‐transfusion hepatitis C virus infection. N Engl J Med 1992;327(6):369‐73. [MEDLINE: ] - PubMed
Farci 2000
    1. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288(5464):339‐44. [MEDLINE: ] - PubMed
Giuberti 1994
    1. Giuberti T, Marin MG, Ferrari C, Marchelli S, Schianchi C, Degli Antoni AM, et al. Hepatitis C viremia following clinical resolution of acute hepatitis C. J Hepatol 1994;20(5):666‐71. [MEDLINE: ] - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Ann Intern Med 2001;135(11):982‐9. - PubMed
Knodell 1981
    1. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1(5):431‐5. [MEDLINE: ] - PubMed
Lauer 2001
    1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41‐52. [MEDLINE: ] - PubMed
Marcellin 1997
    1. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long‐term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon‐alpha therapy. Ann Intern Med 1997;127(10):875‐81. [MEDLINE: ] - PubMed
McHutchison 1998
    1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21):1485‐92. [MEDLINE: ] - PubMed
Orland 2001
    1. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33(2):321‐7. [MEDLINE: ] - PubMed
Pagliaro 1994
    1. Pagliaro L, Craxi A, Camma C, Tine F, Marco V, Lo Iacono O, et al. Interferon‐alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994;19(4):820‐8. [MEDLINE: ] - PubMed
Poynard 1985
    1. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Controlled Clin Trial 1985;6(4):271‐9. [MEDLINE: ] - PubMed
Poynard 1988
    1. Poynard T. Evaluation of the methodological quality of randomized therapeutic trials [Evaluation de la qualité méthodologique des essais thérapeutiques randomisés]. Presse Med 1988;17:315‐8. [MEDLINE: ] - PubMed
Poynard 1996
    1. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: effect of dose and duration. Hepatology 1996;24(4):778‐89. [MEDLINE: ] - PubMed
Poynard 1998
    1. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426‐32. [MEDLINE: ] - PubMed
Poynard 2000
    1. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31(1):211‐8. [MEDLINE: ] - PubMed
Poynard 2001
    1. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34(5):730‐9. [MEDLINE: ] - PubMed
Quin 1997
    1. Quin JW. Interferon therapy for aute hepatitis C viral infection ‐ a review by meta‐analysis. Aust NZ J Med 1997;27(5):611‐8. [MEDLINE: ] - PubMed
Sacks 1987
    1. Sacks HS, Berrier J, Reitman D, Ancona‐Berk VA, Chalmers TC. Meta‐analysis of randomized controlled trials. N Engl J Med 1987;316(8):450‐5. [MEDLINE: ] - PubMed
Seeff 1997
    1. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26(3 Suppl 1):21S‐8S. [MEDLINE: ] - PubMed
Seeff 2000
    1. Seeff LB, Miller RN, Rabkin CS, Buskell‐Bales Z, Straley‐Eason KD, Smoak BL, et al. 45‐year follow‐up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132(2):105‐11. [MEDLINE: ] - PubMed
Thevenot 2001
    1. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001;8(1):48‐62. [MEDLINE: ] - PubMed
Tine 1991
    1. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non‐A, non‐B chronic hepatitis. A meta‐analysis of randomised clinical trials. J Hepatol 1991;13(2):192‐9. [MEDLINE: ] - PubMed
Villano 1999
    1. Vilano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection. Hepatology 1999;29(3):908‐14. [MEDLINE: ] - PubMed
Vogel 1999
    1. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999;31(Suppl 1):189‐92. [MEDLINE: ] - PubMed
Ware 1999
    1. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health‐related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30(2):550‐5. [MEDLINE: ] - PubMed
Zeuzem 2001
    1. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa‐2a in patients with chronic hepatitis C. N Engl J Med 2001;343(23):1666‐72. [MEDLINE: ] - PubMed

References to other published versions of this review

Thevenot 2001a
    1. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001;8(1):48‐62. - PubMed